text:
NWO Takeover: Ukraine President Turns Government Over to 'National Security', Ukraine People To 'The State'
President's address to the Ukrainian people on the occasion of flu epidemic in Ukraine
[excerpts from address:]
Dear fellow citizens! I address you in performance of my constitutional duty under the Article 106 of the Basic Law of the state. The reason is the emergency epidemic situation in the country.
Infections of viral origin, including the A/H1N1 flu, are rapidly spreading across Ukraine. The emergency is evident in the scale of the epidemic: the speed and the geography of its spreading, rapid progress of the illness and the exceptional number of deaths. People are dying. The epidemic is killing doctors. This is absolutely unprecedented and inconceivable in the XXI century.
All the limits have been exceeded - even those under the Constitution that determine my actions as the President.
Second. The A/H1N1 virus is easily mutating. It has travelled across half of the globe before coming to Ukraine. This means that the virus has become particularly pathogenic.
At the same time I instruct the Government and the Ministry of Health to immediately start preventive and promotional work in areas where there is no epidemic, targeting primarily the special risk groups. [mandatory vaccinations?]
We must change the system. We must change the entire system of government in Ukraine. But now, in this moment there is no time for waiting or remonstrance.
National Security and Defense Council should become the center of decision-making. Failure to comply with its orders will immediately result in application to the law enforcement authorities.
I remind all the responsible persons and draw attention to all of my orders, made in Lviv four days ago. In three days the deadline for compliance with these orders expires. With my decree I put Minister of Health and Chief Sanitary Inspector of Ukraine into the Council for National Security and Defense.
I appeal to all of you, dear fellow citizens, to show solidarity, mutual support, and strictly adhere to all the safety regulations regarding protection of your health and lives.
For not a single moment you will be left alone by the state.
This is a very dramatic development. The sitting president of Ukraine has officially declared that the so-called swine virus is mutating and has become "particularly pathogenic', made the statement that "We must now change the entire system of government in Ukraine", and issued orders to turn the government over to the 'National Security and Defense Council'. In addition he has ordered the "Government of Ministry and Health" to begin what appear to be mandatory vaccinations in certain regions. Remarking also that "All limits have been exceeded - even those under the constitution that determine my actions as the president", he is stepping aside, and, in an amazingly Orwellian statement has turned the people of Ukraine over to the care of "the state" [see last line].
Although not mentioned, it certainly follows that the upcoming presidential elections in Ukraine will be cancelled. Martial law is the only conclusion possible, and understanding the big picture, the harsh reality is that this "change in government" will be permanent .
Ordo ab chao...the NWO has just destroyed another country. Another harsh reality...they are just getting warmed up. Watch out bordering countries Romania, Hungary, Poland, Belarus, and other neighboring ones, the next story will be of how it is 'spreading'. (America?)
see: Ukraine Update: NWO Takeover 11-1-09 follow links back for full picture
also: Swine Flu Scam: A New Twist Around Every Corner 10-21-09 "In fact, it is quite possible that one of these days the new story going out to all the world may be... dum da da dum ...that the 'virus' has mutated and has become extremely virulent...or something along these lines."
Psalms 145:18 The LORD is nigh unto all them that call upon him, to all that call upon him in truth.
by tom m. at 1:47 PM Labels: 'swine '09' , nwo 'vaccine' agenda


As a financial journalist over the last decades, I have wrestled with the concept of value. It is, naturally, fundamental to a discussion of prices, markets and other such things with which money scribes concern themselves. Before, as a bond trader, 1980s Master of the Universe (and, increasingly at the time, coke addled legend in my own mind) I traveled the world's financial capitols where I met legions of vastly overpaid financiers who could quote you the price of everything, but understood the value of nothing.
In a very revealing moment not long ago, President Obama showed how out of touch he is - to be fair, most other politicians exhibit the same ignorance - about how rapidly the mood of the electorate is changing toward this nation's drug policies, and about how sophisticated in general people are becoming in their analysis of the issues involved.
As the economy slows, driven in large part by the drying up of credit in the wake of the housing bust, state and local government finances are being strained in a way that hasn't been seen for many years. According to the National Association of State Legislators, the states overall are facing a massive $40 billion budget shortfall. This is very bad news for the $19 billion a year public side of the treatment business, where state contributions account for over 60 percent of revenues.
In a previous incarnation as a technology writer for publications like Red Herring and Telephony, I had the privilege to cover voice-over-Internet-protocol, VOIP, during Internet telephony's early days in the mid to late 1990s. At the time, the pundits were predicting, but it was by no means certain, that VOIP would sweep the nation as a highly disruptive technology in the telecommunications industry, bringing lower prices and greater transparency to consumers. Later on, a few years later fresh out of treatment and having landed a little early sobriety job as the Business Editor of the tiny Boca Raton News, a report crossed my desk that got me quite excited.
For years, we at Treatment Magazine have watched as one addiction treatment entrepreneur and investor after another focused their time, energy and capital on the high-end of the addiction treatment marketplace. CRC abandoned its affordable moniker after buying Sierra Tuscon in 2005, and even affordable care icons like The Right Step's George Joseph have caught margin fever.
For those who have waited years and years through the "Just Say No," the insidious rise of the Prison Industrial Complex and the overall absurdity of our nation's policies toward addiction, the time of reform has finally come.
The idea of suing a casino for one's gambling losses may to most seem absurd, and to us it did too, until we heard Arelia Taveras' story.
Taveras says she lost about a million dollars in Atlantic City - she admits she pilfered client escrow accounts to finance her habit - in a gambling run that went out of control. And now she's suing a group of casino's for $20 million, saying the casinos knew she was out of control because, for example, she would gamble for days straight while actually falling asleep at the tables.
Taveras probably won't get a dime from her efforts - and maybe she doesn't even deserve to - but her suit illustates a key point about gambling, which is that gambling addicts are, and always have been, a casino's best customer.
Our Special Report: Medical Models this month examines the increasing use of more medically oriented modalities in the treatment industry, which up until relatively recently has employed spiritual and psychosocial models almost exclusively in the treatment of addiction.
If you count the birth of the modern treatment industry as starting with the introduction of the Minnesota Model, then the modern treatment business is well over 50 years old. I have studied many industries as a financial journalist, but never before have I run across a business as mature as the treatment industry that is still as fragmented.
While putting together this month's Special Report: Therapeutic Schools, we came across some seamy professional practices that are quite common among therapeutic schools and wilderness programs, and also practiced in the treatment industry, but we believe to a lesser extent.
Last month, federal prosecutors accepted the criminal guilty pleas of top Purdue Pharma executives, including its medical director, as well as that of the company itself, in what has finally been exposed as among the most egregious cases of drug company narcotics sales malfeasance in U.S. history.
Using outright lies and deceptions in its marketing efforts to doctors regarding the addictive risks of OxyContin, Purdue Pharma drove sales of the now infamous pain killer to enormous levels. In a five year period beginning in 1996, sales of OxyContin soared more than 30 fold, reaching major blockbuster levels of over $1.5 billion.
"Ted, Do You Have a Minute...?"
A little over a year ago, Hanley Center CEO Terry Allen asked me to step into his office. I had been waiting in the executive office foyer for development director Terry Lehman to discuss a cover story we were planning on Hanley, which was one of Treatment Magazine's biggest advertising clients.
Saying "Ted, do you have a minute?" Allen waved me over, and, as I always enjoyed talking to Terry, I walked in with a big smile on my face. That's when he dropped the hammer: "Ted, we've heard that you were arrested on possession charges."
We've been getting a lot of emails lately from industry participants reviewing HBO's addiction documentary, with the majority finding the widely publicized cable series wanting.
Many years ago, Don Mullaney, the founder of one of South Florida's most successful treatment enterprises, Behavioral Health of the Palm Beaches, BHOPB, bought a then rather run down residential property in the tiny seaside village of Palm Beach Shores, eventually planning to make the units part of his Florida Model operation. Some homeowners in the village, which consists of a collection of beach front condos and hotels as well as just a few city blocks of old Florida style homes, initially planned to block Mullaney's plans, but then relented and have since developed quite cordial relations with BHOPB, which they view as a high-quality operation.
Since the birth of modern American substance abuse treatment over 50 years ago with the introduction of Hazelden's Minnesota Model, the U.S. addiction treatment system has emerged as world's gold standard. Today, our private treatment facilities attract people from the far corners of the earth seeking a new life based on sobriety and abstinence from mood altering chemicals.
In his farewell speech in 1960, President Dwight Eisenhower famously described the rapidly expanding influence of something he identified as a powerful "military industrial complex," warning that such a complex was then beginning to be built around a growing standing military, the burgeoning armaments industry and the new federally funded scientific research community. In the councils of government, we must "guard against the acquisition of undue influence by the miltary industrial complex," he cautioned. 50 years later, critics of the nation's drug policies, borrowing from Eisenhower's coined phrase, have begun to warn of a growing "prison industrial complex," pointing out that powerful groups who have a vested interest in continuing the failed War on Drugs are blocking crucial efforts to reform the nation's misguided and highly punitive approach to drug addiction.


text:
Ericodesma är ett släkte av fjärilar. Ericodesma ingår i familjen vecklare.

Kladogram enligt Catalogue of Life:

Källor

Vecklare
Ericodesma

redpajama_set_name: RedPajamaWikipedia


text:
Covid-19, FDA, Kefauver-Harris Amendments
FDA Shouldn't Keep Safe Drugs off the Market
I forgot to post this article 30 days after it appeared in the Wall Street Journal. Thanks to Brian Schwartz for reminding me.
Congress's mandate that medications be proved effective is unnecessary and delays potential cures.
By Charles L. Hooper and David R. Henderson
The federal government requires pharmaceutical companies to prove that their drugs are both safe and effective before putting them on the market. Before 1962, companies needed to prove only safety. While there is some appeal to this two-hurdle approach, evidence suggests that there is only a slight benefit and a tremendous cost. With the Covid-19 pandemic sweeping the world, there has never been a better time to revoke the Food and Drug Administration's efficacy requirement.
The thinking behind the FDA's two-hurdle approach is that ineffective drugs cost money and impose an opportunity cost: While the ineffective drug is being used, potentially effective ones are not. But researchers who have studied the 1962 law, known as the Kefauver-Harris Amendments, have concluded that before it was enacted, ineffective drugs were a small percentage of the market and therefore not much of a problem.
Further, the Kefauver-Harris Amendments dramatically increased the time and cost of getting new drugs approved. Evidence provided by University of Chicago economist Sam Peltzman suggests that the number of new drugs approved dropped by 60% in the decade following the law change. We have fewer ineffective drugs, but also far fewer effective ones than we could have had.
That's not all that's wrong with the Kefauver-Harris Amendments.
Before 1962, patients and doctors needed to try drugs to see if they worked for a particular patient at a particular time. It's called trial and error and, despite the change in law, is still the standard medical approach.
To understand how little the FDA's two-hurdle approach contributes, consider Merck's Keytruda (pembrolizumab), which has recently become one of the hottest drugs on the market. Keytruda got some good press after Jimmy Carter, who was suffering from melanoma, was diagnosed as cancer-free after taking it. Mr. Carter was lucky because in one clinical trial Keytruda destroyed or reduced the tumors in only 34% of patients. Keytruda—which was the fourth biggest-selling drug globally in 2018 and brought in worldwide revenues of $11.1 billion last year—is far from a sure thing.
Does the FDA, which approved Keytruda as safe and effective for melanoma, know which patients will benefit from it? No. The potential benefits described on the drug's label are what happened to strangers in another time and place. Patients still have to try Keytruda to know if it will help them. An FDA approval for efficacy is largely duplicative.
Enter Covid-19, the disease caused by the new coronavirus, SARS-CoV-2. There are no proven therapies to treat an infection of that virus. One of the most promising candidates is Gilead Sciences ' remdesivir, which has shown some potential in treating other coronaviruses, such as SARS and MERS. Due to its use in treating Ebola infections, remdesivir is known to be generally safe.
With the FDA's two-hurdle requirement in place, however, remdesivir must be proven effective in clinical trials before it can be sold for widespread use in Covid-19. These clinical trials take time, and they still won't answer many of the questions doctors have about the drug's use against Covid-19 now. What's the right dose to get remdesivir into the lungs? How early should it be given? If it is given to sick patients already on ventilators in hospitals, will it help? All these things will depend on the individual patient.
And then, even if remdesivir is approved by the FDA, patients and doctors will still resort to trial and error, because the success rate won't be 100%.
Instead, the FDA should allow patients and doctors to try remdesivir today. We know it's safe, and there are no other proven therapies. With more widespread usage, the medical community will have a tool to fight back against Covid-19. Controlled clinical trials can continue largely as they normally would. Though access to an experimental therapy won't be an incentive to join a clinical trial, many others remain—such as excellent free care and a sense of pride in helping society and other patients. This two-pronged approach would not only potentially save thousands of lives but also provide much more information.
If you were diagnosed with Covid-19 today, would you choose to take nothing? Or would you want a safe drug that has shown some potential against the virus? We suspect the great majority of Covid-19 patients would choose the latter option. And they would get it today, not months from now, when it would be of no use to them.
This same process plays out every day with other conditions that can be more dangerous than Covid-19. While patients and doctors continue to resort to trial and error out of necessity, the government insists that they initiate their experiments only after the FDA has completed its. This is a critically flawed approach to medicine.
Even as the pandemic robs Americans of their jobs, health and lives, it could reward us with a silver lining if we use the opportunity to take a hard look at our drug-approval process. Revoke the FDA's drug-efficacy requirement.
Mr. Hooper is president of Objective Insights Inc., a company that consults for life-science companies. Mr. Henderson, a research fellow with the Hoover Institution, was senior health economist with President Reagan's Council of Economic Advisers.
Categories: Public Health Regulation
Thomas Hutcheson
May 25 2020 at 10:56am
How much difference would it make vis a vis just requiring providers to give prescribers the information on effectiveness. I think the problem is that it is really difficult to know whether a new drug is cost effective, whether that information is generated up front or over time with use.
Alan Goldhammer
May 25 2020 at 7:31pm
Why not bring laetrile back on the market. It was also a safe drug.
Was it? Quick google search says it may cause cyanide poisoning
Grant Gould
May 26 2020 at 7:22am
I'm a bit confused by this analysis. How can you determine whether a drug is safe or not without reference to the conditions it cures? After all, chemotherapy drugs eg are extraordinarily unsafe by any effectiveness-independent measure, it's only that they are effective against cancer that lets us call their nastier effects "safe".
Safety presumably is a relative measure of the drug's side effects against its benefits, and so if you don't know it's effective as to its alleged benefits you can hardly define what it means for a drug to be safe.
If you're going to drop the effectiveness requirement, why not just drop the safety requirement as well and be done with it? Require testing and disclosure and let doctors and patients do the tradeoffs past that. It would be far simpler than trying to make some objective standard of "safety" without regard to whether your counterfactual is headaches or hepatitis.
You ask:
How can you determine whether a drug is safe or not without reference to the conditions it cures?
That's a good question. Interestingly, though, the FDA did just that for 24 years, between 1938 and 1962. So somehow they figured it out.
Tom DeMeo
May 26 2020 at 12:40pm
We often read posts by Prof Henderson where he cites a rhetorical flaw in an argument. "So somehow they figured it out" is such a flaw.
The position cited here reduces the role of the FDA. With that comes a different liability profile for selling such drugs, and a shift in burden in the role of doctors.
What if the FDA made no finding on Remdesivir? It is entirely possible that no patients would get to take it because the change in liabilities would crush any viable business model for producing drugs with liability risks.
Charley Hooper
While liability is an important issue, the FDA doesn't offer much protection today, even with approvals based on safety and efficacy.
Consider Merck's Vioxx, which was approved by the FDA as a safe and effective drug. When a subsequent clinical trial questioned Vioxx's safety, Merck was nearly buried in lawsuits.
I think that's right, although I would be interested in what my co-author thinks.
It's hard to believe that liability "would crush any viable business modeler producing drugs with liability risks." There are literally thousands of products sold, and probably millions, for which there is no government agency insisting on a showing of efficacy. Yet those products get produced.
But consider the worst case: drug companies need FDA approval to ward off liability suits. As Charley points out above, they might get sued even if there is FDA approval. But if drug companies needed FDA approval of efficacy in order to be willing to produce, then they would seek it. Our proposal would have zero effect. I would predict, though, that companies would produce some drugs without going to the FDA to seek approval for efficacy.
And my prediction is based on current practice. Look at the large number of drugs that doctors prescribe for ailments where the FDA has not approved their efficacy in those uses. Many cancer drugs, for example, are approved for cancer A and doctors get creative and try it on cancer B, an off-label use, and voila, it works on some patients.
Regarding the liability question, that's not my area of expertise. However, my understanding is that doctors and drug companies are regularly sued even with whatever cover an FDA approval offers.
Thanks David for posting this. Nice to see some discussion of how you expect us to find out which drugs work, although personally I want a lot more detail than just trial and error.
Controlled clinical trials can continue largely as they normally would. Though access to an experimental therapy won't be an incentive to join a clinical trial, many others remain—such as excellent free care and a sense of pride in helping society and other patients. This two-pronged approach would not only potentially save thousands of lives but also provide much more information.
I think it is interesting that you suggest controlled trials can continue on largely as they normally would. What's the incentive for a drug company to run clinical trials? Would you favor not having Medicare/Medicaid pay for drugs until they've undergone clinical testing showing efficacy?
I also think it is funny that you suggest in one sentence that you don't think the incentive to join a clinical trial would be reduced much, and then in the next paragraph you ask who would choose to take nothing vs. an experimental drug that has shown some potential against Covid-19? In a clinical trial, you might get the experimental drug, but you've got just as good of a chance of getting a placebo. If your choices are 50/50 chance in the clinical trial of getting the drug, or 100% by not being in the trial. Which do you think most people would choose?
It's also lucky that you chose to highlight remdesivir, which has shown some efficacy in clinical trials, vs. hydroxychloroquine, which had a lot of anecdotal support, but whose benefit has been completely evaporated when looking at the evidence, and instead caused active harm.
Nice to see some discussion of how you expect us to find out which drugs work, although personally I want a lot more detail than just trial and error.
Even with clinical trials, we still need to resort to trial and error. That's what we rely on today. If you want something better than trial and error, we'll need to come up with a better system.
What's the incentive for a drug company to run clinical trials?
Clinical trials provide information. If the expected value of that information is greater than the expected cost of the clinical trial, and the company has no more enticing prospects (not all investments will be funded), then the drug company will initiate that trial.
The value of that information could be large. Imagine launching a drug for bladder cancer with the message that it might have some efficacy versus saying that only 20% of 150 patients in a clinical trial recurred within two years versus 60% on standard therapies. That information has tremendous value for patients and physicians.
I also think it is funny that you suggest in one sentence that you don't think the incentive to join a clinical trial would be reduced much, and then in the next paragraph you ask who would choose to take nothing vs. an experimental drug that has shown some potential against Covid-19?
If you treat people like lab rats—raw materials with no rights—then, yes, you may have a hard time getting enough patients for a COVID-19 trial. If you treat them as humans—ends in themselves—and make it worth their effort, then you shouldn't have any problem.
Yes, but it is trial and error that is backed up by scientific evidence. It's true that even after running a clinical trial, we don't know exactly who a drug will benefit. Although we're often at least part of the way there through biomarker analysis, like this recent readout of data that hopefully leads to us being able to prospectively identify the patients that will respond best to a specific immuno-oncology treatment. But clinical trials for efficacy at least give some guideposts, if a drug passes that, you at least have decent confidence that a drug in the average patient will do more harm than good. For drugs that haven't proven efficacy, you're much safer assuming the opposite.
You seemed to conveniently leave out the most important part of this, those patients and physicians are not the people paying for the drugs. I'm guessing that you would prefer that this was not the case, that patients were more responsible for shouldering at least a portion of the cost themselves, as opposed to having zero idea of what a drug even costs, if so, I'd be in agreement with you. But, that's not the world we live in, the world we have is one where Medicare picks up the tab for roughly a third of all drug spending, and they have no ability to negotiate on pricing. Given that, what do you expect to happen when drugs are on the market with no evidence of efficacy? Will Medicare be required to buy these? Or, will they be allowed to require some form of clinical trials to show efficacy before they pay for anything? If so, do you think that private insurers might want to piggyback on that effort so that they don't have to run their own clinical trial apparatus? Would that world look very different from what we have now?
Maybe someday we'll be able to tell which patients will benefit beforehand, based on biomarkers or something else, but we aren't there yet. When we get there we can discuss the implications.
Regarding clinical trials as guideposts, I'm agreeing with you. I'm not anti-clinical trial. I think clinical trials can offer a lot of good information. But I want them to be initiated when there's the promise of offering good information rather than something a drug company is forced to do when checking off the boxes of an FDA submission.
Regarding Medicare paying for drugs, there are many subtleties and moving parts involved. The drugs used in hospitals (Part A) are reimbursed differently from drugs prescribed in a hospital for at-home use (Part B) and differently from outpatient drugs prescribed by an office-based physician (Part D). Some Medicare patients are covered by private insurance. Depending on the setting, there are drugs that Medicare isn't required to pay for. Frequently it's the hospital or the health plan that decides which drugs to cover.
In other words, the linkage between "FDA approval" ==> "Medicare must pay for it" does not exist today.
No, we're not there yet. We're getting closer in some areas, which is what the whole "personalized medicine" revolution is supposed to be about, but I think by the time we get "there" that means we're probably at a stage where rational drug discoery makes sense, and where the risk that we see in clinical trials today is not nearly as big of an issue. Right now the problem as I see it is, biology is really messy, and we've got very little idea what will work and what won't before we try it in a whole bunch of people and compare it to some kind of control.
Glad to see we agree on the importance of clinical trials. I'm not at all wedded to the FDA model of drug efficacy testing, but before getting rid of it I'd like to have a pretty good handle on what the new incentive structure looks like to provide the market with that kind of data.
No offense intended, but this seems an awfully lot like dodging the question. Yes, the drug payment environment is complex (I've written a whole series of pieces on how we're actually paying a far larger fraction of our healthcare budget on pharmaceuticals than it looks like, because the CMS data doesn't include those really expensive hospital administered drugs in their drug category). However, just because Medicare doesn't purchase all drugs on the market, doesn't change the fact that they do pay for something like a third of all drug spending , and private insurers pay for most of the rest.
If the FDA isn't responsible for validating efficacy any longer, I see a couple of possibilities. 1) You replicate this functionality within Medicare/Medicaid and/or large insurers pool together to do it. or 2) There's some rule that Medicare has to cover drugs that pass PhI safety, maybe at some kind of reduced rate. The first is definitely more palatable to me, but doesn't seem to change much from the status quo? I guess the difference is that some companies may choose to sell experimental medicines to people who pay out of pocket, either because they are rich or they don't have any other options, or both. That makes the world a bit better from a freedom perspective, but otherwise doesn't seem to make many people better off, since those drugs are likely to do more harm than good, and we don't even get the benefit of the knowledge that you get if it is part of a clinical trial (i.e. all those companies offering unproven stem cell therapies in less regulated markets aren't carefully collecting data).
These are always easy statements to make by anyone unfamiliar with what is in a new drug application submitted to a regulatory agency. When I was still working in regulatory affairs at PhRMA, I received a communication from a pediatrician in Illinois taking pretty much the same view and that he would be happy to review data on drug safety and efficacy in his spare time. This was laughable. When we were negotiating the renewal of the Prescription Drug User Fee Act back around 2006 we hired an economist to help us do some quantification of the FDA review process. FDA provided us with a lot of information so that we could do our analysis and they had their own economist double checking thing. IIRC, the average application required over 100 FTEs throughout the entire process from submission of the investigational new drug application to the meetings that are held during protocol development and on to the review of the final submission. One pediatrician in Illinois working on weekends cannot do this kind of work as I explained to him responding back.
Now David and Charlie argue that parts or maybe all of this review are wasteful and that we should allow 'safe' drugs on the market. What is meant by safety? As noted above, many chemotherapy drugs are not particularly safe. We know there are a number of other drugs that also pose risks to certain populations. As I noted in my post above, laetrile is safe but totally ineffective. Should it be allowed on the market as some people continue to believe it to work on certain kinds of cancer.
Most of the people who write about these types of approaches have little understanding of the regulatory process and the decision making that goes on. Furthermore, many physicians have an incomplete understanding of the drugs they prescribe (just look at the over prescription of opioids). It's fine to say this should be a decision between the patient and his/her doctor but without the baseline of knowledge contained in the FDA approved prescribing information this is not going to be a particularly informed decision. Until, I see a proposal from the libertarian community that addresses the information deficit, I cannot take them seriously.
Even with the exhaustive FDA review process, can the FDA tell which patients will have an adverse event? No. Can the FDA tell which patients will have a favorable outcome? No.
If the current system is so good, why do physicians and patients still need to rely on trial and error?
"While there is some appeal to this two-hurdle approach, evidence suggests that there is only a slight benefit and a tremendous cost"
Ironic that the two-hurdle approach was adopted even though it does not pass its own two hurdles. It's not safe because of the side effects of keeping effective drugs off the market. It's also not effective because ineffective drugs were a small percentage of the market and therefore not much of a problem and also because patients and doctors need to go through a trial-and-error phase anyways.
Some people like to say that they're not pro-regulation, only pro good regulation. If so, then they should demand that any regulation be proven safe and effective in random control trials before widespread adoption.
Well done, BC. You've actually anticipated much of the book on the FDA that Charley is working on and, in fact, the subtitle he is likely to use.
Good points. I think a lot of regulation follows this pattern:
(1) Identify the risk of X happening, where X is something bad and the root emotions are fear and distrust.
(2) Without clearly showing whether X is actually happening, the probability that X will happen, or the how the costs of accepting X are greater than the costs of trying to prevent X, a new regulation is put in place. In other words, there's a lack of numeracy and clear thinking.
(3) The intentions of the regulation to prevent X are used to judge the merits of the regulation rather than the actual mechanisms and outcomes of the regulation
(4) The new regulation becomes the default case and all challenges are waved off with mentions of how X might happen sans the regulation. In other words, there's a lack of curiosity, inquiry, and clear thinking.
(5) The wisdom and motives of challengers are questioned. This helps solidify the belief that virtuous and smart people know that the regulation is a good idea.
(6) Serious challenges to this regulation must prove that X isn't happening, X won't happen, or that the costs of trying to prevent X are greater than the costs of X itself. Those who challenge existing regulations face a tougher challenge than those who advocate for new regulations.
COLLECTION: PUBLIC HEALTH
The article you're reading is part of Econlib's Public Health collection. Explore other Public Health articles:
Regulation: It's much worse than you think
Noubar Afeyan on Academia, Business, Immigration, and the American Dream
Thoughtful Pieces on the Lessons of COVID-19
The Big Lesson of 2020: Government Failure

redpajama_set_name: RedPajamaCommonCrawl


In many applications, a summarized result, e.g. the number of critical off-limit conditions or an integral result over a specific period of time are of interest to draw implications for the future. Among these applications are the shelf life monitoring of consumables, pharmaceutics or food as well as the condition monitoring of technical infrastructure. Sensors usually require an electrical energy source for measurement and storage of data. Here, two non-electrical examples are presented that register data without the need of electrical energy: a passive temperature-time integrator (TTI) and a mechanical binary counter for threshold events. The TTI makes use of microfluidic flow of specific food ingredients into microcapillaries that depends on viscosity and time. The binary counter based on surface MEMS allows counting and storing threshold events, e.g. mechanical shocks. Both sensors can easily be read out e.g. by RFID.
Hoffmann, Martin / Wedrich, Karin / Schmitt, Phillipp / et al: Non-electrical sensing and storing an alternative to electrical energy harvesting. 2017.


Our production cycle is monitored thoroughly so high quality standards will be applied for our products. Every procedure of our production cycle is pre-designed, checked and tested and all our production process from the raw material to packing and delivery to our customers is recorded in every detail.
- Wire Rod Pickling and phosphatation.
-Heat treatment in order to gain the necessary mechanical properties.
-Standard packing for immediate distribution.
One of the main goals of the company is to adopt the most modern technologies in order to increase it's productivity and to continually improve all factors affecting the quality of it's final product. The management employs an 'open door' policy with respect to it's personnel thereby discussing all serious propositions, ideas, methologies and innovations which may improve output, increase quality, enhance the working environment and reduce company costs.Already, as of June 1998 an electroplating plant has been installed with the intent of improving and differentiating the company's product range.


text:
IRS Crackdown on Tax Evasion Leads Swiss Banker to Enter Guilty Plea
Posted on August 26, 2016 | Share
Many U.S. citizens opened offshore Swiss accounts because of the strong privacy laws in Switzerland that were supposed to help these accountholders keep their identities confidential and their information from the Internal Revenue Service. Unfortunately, the Swiss privacy laws turned out not to have really provided much protection at all. As the IRS and Department of Justice have begun aggressively cracking down on banks and bankers, many are entering into plea deals that often involve giving up information on their clients.
One banker, for example, recently plead guilty of facilitating tax evasion between 2002 and 2009. The banker worked for Credit Suisse AG and oversaw a portfolio of American accounts which, at one time, had an aggregate balance of around $700 million.
Among many things, this 48-year-old banker has been accused of convincing U.S. accountholders that their identities could be concealed. The fact is, however, that his bank entered into a plea deal, paid a $2.6 billion fine and gave up information on accountholders. The banker is now also providing details to the IRS of the steps he allegedly took to facilitate tax evasion, and two of his co-defendants also entered guilty pleas.
With banks and bankers giving the IRS and DOJ extensive details on offshore accounts, as well as on how tax evasion was facilitated, every accountholder should be very nervous if they have any undeclared offshore funds. A Boston tax evasion attorney can help those who are worried their information may be turned over and can provide assistance to accountholders who are already facing an investigation.
Swiss Bankers Caught in IRS and DOJ Crackdown
The 48-year-old Swiss banker who recently agreed to plead guilty to facilitating tax evasion has been considered a fugitive since 2011. He is a citizen of Italy and a resident of Switzerland, but none of this insulates him from being caught up in the aggressive crackdown by the IRS and DOJ.
He was accused of doing many different things to help U.S. accountholders hide money, which resulted in as much as a $1.5 million loss of revenue to the U.S. government. For example, he reportedly hid his identity and the purposes of his visits to the United States when he came to meet with clients.
He helped clients conceal their identities on accounts by structuring ownership in those accounts in the names of corporations, trusts, partnerships and foundations. He also structured withdrawals so it would be easier for accountholders to obtain their money and bypass reporting requirements, and he held the mail of U.S. accountholders so it would not come to the United States.
All of the details about how the banker helped U.S. taxpayers hide their identities and access their cash secretly are all coming out, and this information can help the IRS and DOJ as they make further efforts to go after banks, bankers and accountholders. Those who are worried they could be caught up in the crackdown should consult attorney Kevin Thorn right away to find out what options they have to try to protect themselves.


Overview: Wound care products are mainly intended for safeguarding timely wound healing and active control of infection. There are many wound products accessible in the market, from over-the-counter to prescription products. Maximum wound care products are topical and are permitted as medical devices, but a few products such as biologics are scrutinized under strict regulatory guidelines. The wound biologics market is very unified at present, with the US, Europe, and Japan collectively accounting for a significant share of the product sales. The principal variables are the regulatory trails essential for obtaining marketing approval, with the US regulatory necessities being very different when compared to most of the other nations. Furthermore, the standard of care fluctuates significantly between industrialized and emerging countries, making it tougher to conduct sufficiently precise clinical trials in a global setting.
Skin substitutes, growth factors, and enzyme-based products are the major types of biologics in the market. Nearly half of the skin substitute market is dominated by the major players in the market. Organogenesis, Molnlycke, and Smith & Nephew are the major players in this segment.
The growth of the market is driven by an increase in aging population, increasing number of people suffering from diabetes, growing acceptance of innovative technologies for complex wound treatment, and rising incidence of chronic wounds. However, the complex regulatory process and the high cost of biologic wound care are hampering the market growth.
Market Analysis: The "Global Wound Biologics Market" is estimated to witness a CAGR of 12.3% during the forecast period 2017–2023. The market is analyzed based on four segments – products, applications, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the global wound biologics market, followed by Europe, Asia Pacific, and Rest of the World. Nearly half of the market is occupied by North America, with the US being the major contributor to the market growth. In the US, Organogenesis and MiMedx hold nearly half of the skin substitutes market. However, Europe is close to North America with many companies developing advanced technology products. In Germany, Organogenesis and Integra Life Science hold a significant share of the skin substitutes market.
Product Analysis: Skin substitutes, growth factors, and enzyme-based products are the types of wound closure biologics in the market. Skin substitutes is the major segment of the market. MiMedx, Organogenesis, and Smith and Nephew are the key players in the skin substitute market. MiMedx increased its market share from 24.9% in 2015 to 31% in 2016 in the advanced skin substitute market.
Application Analysis: The applications of the wound biologics include chronic wound and acute wound. Acute wound comprises traumatic wound and surgical wound. As the ratio of the surgical wound is higher in comparison with other wound types, the acute wound closure was the major shareholder of the market in 2017. However, the chronic wound is increasing the burden of healthcare expenditure globally. This has increased the demand for innovative products for the treatment, which is expected to experience the fastest growth rate during the forecast period.
Key Players: Organogenesis, Smith & Nephew, MiMedx, and Integra Life Science are the key players in the market. The other prominent players in the market include Pinnacle Transplant, Osiris, Molyncke Health Care, Soluble Systems, Applied Biologics, and Skye Medical.
Competitive Analysis: Many players are using various strategies such as new product launches, clinical trials, market initiatives, high expense on R&D, agreements, joint ventures, acquisitions, and others to increase their footprints in this market. In January 2018, Alliqua BioMedical, Inc. entered a definitive agreement with Celularity, Inc. to acquire all the assets and rights of the company's advanced biologic wound care business. This added Biovance Amniotic Membrane Allograft, Interfyl Human Connective Tissue Matrix, UltraMist Therapy System, and other therapeutic products to Alliqua's portfolio. In January 2016, Human Regenerative Technologies, LLC initiated the building process of its new state-of-the-art amniotic and placental tissue matrix research, development, and processing facility worth $12 million in California, US.
Benefits: The report provides complete details about the usage and adoption rate of wound biologics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Acelity L.P. Inc., BioD LLC, ConvaTec Group plc, Cytori Therapeutics Inc., Intercytex, Macrocure Ltd., Integra LifeSciences, Organogenesis Inc., Smith & Nephew, Molnlycke Health Care, Nuo Therapeutics Inc., Osiris Therapeutics Inc., and Regenerys Ltd.


text:
La Coppa Svizzera 1952-1953 è stata la 28ª edizione della manifestazione calcistica. È iniziata nel settembre 1952 e si è conclusa il 14 aprile 1953.Questa edizione della coppa vide la vittoria finale del Young Boys.

Regolamento
Turni ad eliminazione diretta in gara unica. Le partite terminanti in paritá dopo i tempi supplementari, potranno rigiocarsi una sola altra volta, se persiste il pareggio, si ricorre ad un sorteggio per stabilire la squadra qualificata al prossimo turno. Una prima fase vede la qualificazione di squadre attraverso delle eliminatorie regionali. Al terzo turno entrano in lizza le squadre di Lega Nazionale A e B.

Squadre partecipanti

1º Turno Eliminatorio

|colspan="3" style="background-color:#D0D0D0" align=center|7 settembre 1952

|-
|colspan="3" style="background-color:#D0D0D0" align=center|14 settembre 1952

|-
|colspan="3" style="background-color:#D0D0D0" align=center|28 settembre 1952 (Ripetizione)

|-
|colspan="3" style="background-color:#D0D0D0" align=center|28 settembre 1952 (Posticipo)

2º Turno Eliminatorio

|colspan="3" style="background-color:#D0D0D0" align=center|5 ottobre 1952

|-
|colspan="3" style="background-color:#D0D0D0" align=center|12 ottobre 1952 (Ripetizione)

Trentaduesimi di finale

|colspan="3" style="background-color:#D0D0D0" align=center|26 ottobre 1952

|-
|colspan="3" style="background-color:#D0D0D0" align=center|9 novembre 1952 (Ripetizione)

|-
|colspan="3" style="background-color:#D0D0D0" align=center|9 novembre 1952 (Posticipo)

|-
|colspan="3" style="background-color:#D0D0D0" align=center|16 novembre 1952 (Posticipi)

|-
|colspan="3" style="background-color:#D0D0D0" align=center|23 novembre 1952 (Posticipo)

Sedicesimi di finale

|colspan="3" style="background-color:#D0D0D0" align=center|23 novembre 1952

|-
|colspan="3" style="background-color:#D0D0D0" align=center|7 dicembre 1952 (Ripetizioni)

|-
|colspan="3" style="background-color:#D0D0D0" align=center|4 gennaio 1953 (Posticipo)

Ottavi di finale

|colspan="3" style="backgrund-color:#D0D0D0" align=center|4 gennaio 1953

|-
|colspan="3" style="background-color:#D0D0D0" align=center|11 gennaio 1953

Quarti di finale

|colspan="3" style="background-color:#D0D0D0" align=center|15 febbraio 1953

|-
|colspan="3" style="background-color:#D0D0D0" align=center|22 febbraio 1953 (Ripetizione)

|-
|colspan="3" style="background-color:#D0D0D0" align=center|1 marzo 1953 (Ripetizione)

Semifinali

|colspan="3" style="background-color:#D0D0D0" align=center|8 marzo 1953

|-
|colspan="3" style="background-color:#D0D0D0" align=center|30 marzo 1953 (Ripetizione)

Finale

Finale ripetuta

Note

Fonti e bibliografia
Giornali
Gazzetta Ticinese, annate 1952 e 1953.
L'Express, annate 1952 e 1953.
L'Impartial, annate 1952 e 1953.
Le Temps, annate 1952 e 1953.
Tribune de Lausanne, annate 1952 e 1953.

Collegamenti esterni
 Stagione 1952/53 su RSSSF.
  Archivio digitalizzato de "L'Express".
  "Gazzetta Ticinese", archivio digitalizzato su cbt.ti.ch. (richiede plugin DjVu per la lettura delle pagine).
  Archivio digitalizzato de "L'Impartial".
  Archivio digitalizzato de "Le Temps".
  Archivio digitalizzato della "Gazette de Lausanne".
  Archivio digitalizzato della "Tribune de Lausanne".

Calcio nel 1952
Calcio nel 1953
Edizioni della Coppa Svizzera


I'm following all the instructions (using the EM version of install.txt for Attach Mod v2.4.5, with latest phpBB v2, i.e. phpBB v2.0.22). Install of EM seems to work fine. When installing Attach Mod via EM, I reach the second page of the install, (step 2 of 3). That page has six boxes, each of which lists the following six Warnings with a header saying they were "Reported by the SQL Parser:"
1.  Inconsistent display width specified "INTEGER(20)" in column "max_filesize", statement: 3, table: "phpbb_extension_groups"
2. Identifier "comment" is a reserved keyword (reference: MySQL), statement: 4, table: "phpbb_extensions"
3. Identifier "comment" is a reserved keyword (reference: MySQL), statement: 5, table: "phpbb_attachments_desc"
4. Inconsistent display width specified "INTEGER(20)" in column "filesize", statement: 5, table: "phpbb_attachments_desc"
5. Column "comment" has been found using 2 different data types in 2 tables: VARCHAR(100) in phpbb_extensions; VARCHAR(255) in phpbb_attachments_desc.
6. Column "auth_download" has been found using 2 different data types in 2 tables: TINYINT(2) in phpbb_forums; TINYINT(1) in phpbb_auth_access.
Atea wrote: Ok, I may be stupid, but I tried almost everything and I still can't install Attachment Mod with EasyMOD ... Do I need to do any changes in files, before I can install this Mod with EasyMOD?
edit: I had to do the mod manually. It works good thus far.
Can I add to the allowable file types for attachments?
edit 2: I found that too.
I would like to know if this MOD works even though i have the imageshack mod installed..
hi,i could upload an attachment file when i have posted a message and also preview it but when i have posted and submit it i cant see my attached files in my forum.it hadnt been to attached in my message ..How could i fix this problem ..may be it's about a sql problem or about .tpl file.
I have successfully install attachment mod with few error/warnings but now I can't look at my forum index at all. It shows a message that I have to delete all install/ and contrib/ files. Though I have deleted it, it still shows the message.
What should I need to do?
Thats a tricky one, since most mods either replace code or insert new code. This seems like a bit of a drastic error. I suggest replacing all the files with your backups and installing it manually. then you will find out what is causing the problem..


text:
This page is intended for physicians only. Please consult professional medical service providers for further information.
Are you a physician?
YES | NO
此頁面專為提供醫師參考使用。如需更多資訊,請諮詢醫療專業人士。
請問您是否為醫師?
India as leading country in the application of ologen™ Collagen Matrix and its combined use
2013-01-25 /in News /by aeonastron_ad
India as leading country in the application of ologen™ Collagen Matrix and its combined use
2013 APAO-AIOS symposia recognize India as leading country in the application of ologen™ Collagen Matrix and its combined use with other compounds.
The Aeon Astron sponsored symposium at the 2013 APAO-AIOS Joint Congress1 "Breakfast Debate: ologen™ Collagen Matrix or MMC for Glaucoma Surgery? (GL-SP01)" recognizes India as leading country in the application of ologen™ Collagen Matrix and its use in combination with other compounds. Followed by Dr. Robert Ritch's scientific program on: "The Use of ologen™ in Filtration Surgery (GL-SS08)", the debate further introduced to a video-assisted skill transfer presented by AIOS and ISGS2 "Trabeculectomy: Pearls & Pitfalls; Cipla" in which the collagen matrix implant was recommended by a number of highly recognized Indian members of the national presenting panel3,4,5. According to the audience's response, a large number of the attendees were convinced of the outstanding qualities ofologen™ Collagen Matrix and willing to try or continue using the collagen matrix.
Dr. L Vijaya opened the debate by reviewing the phases of wound healing and the role of Mitomycin-C (MMC) in glaucoma filtration surgery. As MMC-associated complications are dose-dependent, Dr. Vijaya recommended an application with the minimal required dose of MMC with the shortest exposure time possible, as opposed to a localized, high-dose MMC implementation.
In response, Dr. B S Rao brought up the aspect of ologen™ Collagen Matrix implant as an anti-scarring adjuvant and alternative to MMC: with physiological wound modulation and the prevention of wound adhesion and formation of dense scarring, the collagen matrix implant may reduce the chemo toxic hazard – both for the patients and for the surgeons – of applying and disposing of MMC.
In the second round of the debate, Dr. Sathyan P and Dr. Sirisha S reviewed the clinical evidence available to date. In a two-year randomized controlled trial (RCT) by Dr. Cillino et al. (2011), ologen™ Collagen Matrix was used as an adjuvant in trabeculectomy. In agreement with Aravind Eye Hospital's experiences presented by Dr. Sathyan at the debate, the study tentatively concluded that "The implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate."
More RCT's were reviewed with regard to the MMC use. Despite the more-established effectiveness in killing cells and the non-conclusive results on MMC's safety issues, a number of studies do suggest that MMC may increase the chances of post-operative complications. This safety issue is especially significant in treating young patients as "the bleb-related complications are going to be more… the longer you follow them up. (Dr. Sirisha)"*6 A solution to the unmet need for the optimization of filtration surgery – especially in pediatricglaucoma – was yet to be found.
The debate peaked when a new application modality of the ologen™ Collagen Matrix was discussed: the pros and cons of combining collagen matrix implant with low-dose MMC (separate procedures; 0.1 mg/mL MMC or below; in comparison to the commonly used dose of 0.2 mg/mL up) and whether there would be conflicting mechanisms. While ologen™ Collagen Matrix alone may be enough in general situations as proven by the evidence, the implant and the antimetabolites may nevertheless be active during the different phases of wound healing and thus achieving some kind of synergism for scar prevention. This especially could be the case in patients requiring more complicated care, for instance, during repeated or revision surgery post failed trabeculectomy. Some preliminary reports have been published by Dr. Dada et al. (J Glaucoma 2012), Dr. Bordeianu (ESCRS abstract, 2012), Dr. Rosentreter et al. (2010) and Dr. Kohlhaas (2012; 2008), supporting the idea of this combined use of a collagen matrix and an anti-metabolite in the special cases.
To summarize, the combined use of ologen™ Collagen Matrix implant with low-dose antimetabolites (separate procedures) raises the question as to how low an effective dose of MMC could be in order to obtain the desired results with optimal wound healing and reduced bleb-related complications. Further research is also required for new possible combinations, such as the effectiveness of ologen™ Collagen Matrix together with Bevacizumab (separate procedures)7, an anti-VEGF adjuvant presumably suitable for glaucoma surgery patients with AMD or neovascular glaucoma. The exploration of these approaches may help optimize the practice of filtration surgery as well as other glaucoma related surgeries (GDD, revision surgery and NPGS), when a delicate consideration is made between the welfare of patients with more difficult glaucoma situations and the economy of health care.
(Click to see the photos of the events.)
1. Asia Pacific Academy of Ophthalmology (APAO) and All India Ophthalmological Society (AIOS) Joint Congress
2. International Society of Glaucoma Surgery (ISGS)
3. Dr. Murali Ariga (Swamy Eye Clinic and Chennai Glaucoma Foundation) on "Same site phacotrab with ologen implant".
4. Dr. R Ramakrishna (Aravind Eye Hospital; author, co-editor of "Diagnosis & Management of Glaucoma, Jaypee 2013") on "Trabeculectmy with ologen".
5. Dr. Tanuj Dada (Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS; ISGS) on "Trabeculectomy with ologen subconjunctival & subscleral (with subscleral crater)", "ologen subconjunctival with releasable sutures", "ologen subslceral (NPDS with low-dose MMC; separate procedures)".
6. Some abstracts on the application of collagen matrix implant in pediatric glaucoma are to be presented in 2013 SOE, Copenhagen, and 2013 WGC, Vancouver.
7. Other candidates include Ranibizumab, Aflibercept, or small molecular anti-VEGF (TKI), such as Pegaptanib (soaked or intraocular injection).
https://www.ologen.com/wp-content/uploads/2017/04/ologen-logo.png 0 0 aeonastron_ad https://www.ologen.com/wp-content/uploads/2017/04/ologen-logo.png aeonastron_ad2013-01-25 16:38:122017-06-16 14:36:24India as leading country in the application of ologen™ Collagen Matrix and its combined use
Aeon Astron Europe B.V. was incorporated in February 2008 in Leiden, the Netherlands.
Aeon Astron Europe B.V.
J.H. Oortweg 19, 2333 CH Leiden, The Netherlands
ologen™ Collagen Matrix has been approved by Taiwan Food and Drug Administration (TFDA).
ologen™ Collagen Matrix Implantation is viable to assist Treatment of Scleromalacia after Periocular Surgery.
A RETROSPECTIVE STUDY DISCOVERED 41.7% HIGHER RATE OF COMPLETE SUCCESS OF OLOGEN-AUGMENTED AHMED GLAUCOMA VALVE IMPLANTATION THAN CONVENTIONAL METHOD.
© Copyright | Aeon Astron Europe B.V.
EuroTimes And EyeWorld News on ologen™ Collagen Matrix New Horizons: "Novel Applications for ologen™ Collagen Matrix" at the...


text:
marycoal62
https://msmadrid.org/
The mobile version of Minecraft - AKA: Minecraft: Pocket Edition - is being designed to allow for major changes literally. Mojang, the developer of Minecraft Mojang has announced on its website that the team is "restructuring many of the codes to make it possible to create much larger worlds in the future updates," and also changing the AI of the creatures and the inventory system. Mojang announced that Pocket Edition updates will not be released until the end of the year. The sentence is believed to be written while playing with a fluffy cat, or aboard the Death
Uchatoo
You have poked Marycoal62


Thank you for your interest in our Homebuyer Education and/or Financial Literacy Counseling. Please download the attached application and fill it out. Upon receipt of your completed application, you will be contacted by the Housing and Financial Literacy Counselor to schedule an appointment.
We thank you in advance for the opportunity to service you on your road to home ownership and/or your journey to financial freedom.


Grease Chains There are 2 products.
Aceite Motosierras is a high performance lubricat oil made from hihgly refined base oils and special additives with great tackiness and adherence.
Aceite Motosierras BBO is a high performance ecological and biodegradable lubricating oil, exceeding 80% of biodegradability in the CEC L-33-A-93 test.


Dr. Lauren Mutter received a Bachelor of Arts degree from the University Notre Dame. She then earned a Doctor of Medicine degree from Louisiana State University Health Sciences Center in New Orleans, LA. Dr. Mutter went on to complete a Pediatrics Residency and a Pediatric Emergency Medicine Fellowship at the University of Tennessee Health. She is board certified by the American Board of Pediatrics.
Wonderful experience. Caring. Explained everything that was going on to us. Cannot recommend highly enough.


Education Secretary Leonor Briones highlighted the important contribution of learners in the advancement of the educational system in the country by sharing their insights in the various policy, program, and project development efforts of the Department of Education.
"It's a wise move to allow our learners, the adolescents, to participate in our policy development activities so they can tell the older generation what really is happening and what they really need as learners," Briones said during the Third Development Partners' Coordination Forum.
She then shared her admiration for the younger generation.
"Bilib ako sa boses ng kabataan… Yes, the adults have the benefit of experience, but the younger generation is likewise important as they have the energy, commitment, and endurance that are also needed for the betterment of our society and of the world," she expressed.
The forum — with the theme "Addressing Barriers to Education of Adolescents" — is the third leg of the series of DepEd's coordination activities with development partners, following the fora on Alternative Learning System (ALS) and Education in Emergencies (EiE) in 2017.
"The series aims to establish regular avenues for collaboration between DepEd and the development partners to align our directions and efforts, and help us achieve the 10-point agenda of the Briones administration," Assistant Secretary Revsee Escobedo explained.
"We ardently hope that this activity will also create an avenue for selected development partners to share current initiatives in reinforcing positive attitudes and outcomes to education of adolescents," he added.
The series of fora also aims to identify gaps, challenges, and areas of priority action, and set strategic interventions and areas of collaboration to ensure the delivery of a quality, accessible, relevant, and liberating basic education for all.


1 July through 31 December, the European Union is presided over by Luxembourg – a phenomenal example of international diplomatic acclaim without power and influence.
Several years later, these wishes found embodiment. In accordance with the Treaty of Lisbon of 2007, the European External Action Service was established, which took over the planning and implementation of a common European foreign policy. In addition, the European Union continues to genuflect in the direction of small states. "My experience shows that presidencies from small countries are very much involved in the success of reforms," stated the President of the European Parliament Martin Schulz in particular in January 2015 . It would seem that the dreams of small states have come true.
However, the new political weight and constant encouragement have not changed their geographically orientated self-perception. Cyprus, Latvia, Lithuania, Denmark, and several others never let slip any opportunities to remind the rest of their territorial size. In this sense, Luxembourg is no exception. The common theme of all analytical articles about its foreign policy is speculation on how much the influence of the Grand Duchy corresponds to the size of its territory.
True, its main distinguishment from the other countries is in the answer to that question. "Global player" was the epithet that the June issue of the magazine Forum gave Luxembourg on the eve of the assumption of its presidency . "It is widely recognized that Luxembourg's influence, especially in European affairs, exceeds its size," expert Mario Hirsch wrote in a May article for Carnegie Europe .
The only weak point of these characteristics is the lack of concrete examples. Influence is the ability to force others to change their position. For all the world fame of Luxembourg's financial system, it has never been an instrument of foreign policy influence. It is also difficult to count as specific examples those individual episodes recalled by observers in Luxembourg with such pleasure: support for the operations of the USA in Afghanistan in 2001 and the refusal to support the USA in Iraq in 2003. Who noticed it then? These and other instances speak only of the fact that Luxembourg tried to act independently and not that its position influenced anyone else's.


text:
Mayflower Compact
Previous (Mayflower)
Next (Mayfly)
This bas-relief depicting the signing of the Mayflower Compact is on Bradford Street in Provincetown, Massachusetts on the base of the the Pilgrim Monument.
The Mayflower Compact was the first governing document of Plymouth Colony, drafted by English religious separatists known as the Pilgrim Fathers aboard the Mayflower in 1620.
With the charter for the colony incomplete at the time the colonists departed England, the Pilgrims arrived off the coast of New England without a patent. The colony thus had no legal basis, and some non-Pilgrim passengers suggested that the settlers were free to ignore the apparently ambiguous authority of Governor John Carver, as well as their contract with the colony's investors. In response to certain "mutinous speeches," a brief contract was signed on November 11, 1620, promising cooperation among the settlers "for the general good of the Colony unto which we promise all due submission and obedience."
In establishing a governing authority, the Pilgrims turned to the model of their own congregational churches as the basis of government. The colonists would form a "body politic" which would select leaders chosen by the majority, just as separatist congregations had elected their own ministers and governed themselves. The document was ratified by majority rule, with 41 adult male passengers signing.
1 History of the Mayflower Compact
2 Text of the Mayflower Compact
3 Signatories
Many historians regard the document as the forerunner of the United States Declaration of Independence and of the United States Constitution. From its inception on the Mayflower, the idea of self-government based on a social contract would expand in New England town meetings and traditions of local government, and later would influence the establishment of American republican government. John Quincy Adams described the Compact as "the only instance in human history of that positive, original social compact" which he and others took to be the "only legitimate source for government"[1]
History of the Mayflower Compact
Bradford's transcription of the compact.
The Mayflower Compact was signed on November 11, 1620, (O.S.) in what is now Provincetown Harbor near Cape Cod. The Pilgrim Fathers used the Julian Calendar which, at that time, was ten days behind the Gregorian Calendar, signing the covenant "ye .11. of November" (literal). Having landed at Plymouth (so named by Captain John Smith earlier), many of the Pilgrims aboard realized that they were in land uncharted by the London Company. For this reason the Mayflower Compact was written and adopted, based simultaneously upon a majoritarian model and the settlers' allegiance to the king.
The Mayflower carried 102 passengers. Of these, 41 were Pilgrims seeking a new environment where they could practice their religion in the manner they chose. The remainder of the passengers, called "Strangers"by the Pilgrims, included merchants, craftsmen, skilled workers and indentured servants, and several young orphans. William Brewster and other Pilgrim leaders organized the voyage and gathered these "strangers" to increase the chances of the colony's success. The voyage lasted more than two months. When they finally sighted land the captain of the Mayflower knew right away that they were far north of their destination so headed southward. This proved too dangerous and they were forced to turn back and drop anchor in a harbor at the tip of Cape Cod.
Unrest started immediately. William Bradford later wrote that several "strangers" made "discontented and mutinous speeches." Bradford went on to explain that the "Strangers" did not want to follow rules because "none had power to command them." The Pilgrim leaders, with staunch determination to establish a colony amidst the brewing rebellion, knew they needed a temporary government authority. In England, such authority came from the king but in remote America it could only come from the colonists themselves. While still aboard the Mayflower, the Pilgrims and "Strangers" made a written agreement or compact among themselves.
It is assumed that William Brewster, who had a university education, wrote the Mayflower Compact. The pattern of church self-government used by the Pilgrims to establish their Separatist churches in England and Holland served as a model for political self-government in the Mayflower Compact. Almost all the adult male colonists, including two of the indentured servants, signed the document.
By signing the Mayflower Compact, the colonists in no way intended to declare their independence from England. The opening line of the Compact refers to both Pilgrims and "Strangers" as "loyal subjects" of King James. The document is very short. It simply united the signers into a "Civil Body Politic" for the purpose of passing "just and equal Laws…for the general good of the Colony." However, those few words conveyed the idea of self-government for the first time in the New World.
From its crude beginning in Plymouth, the idea of self-government in New England evolved into town meetings and gradually spread into larger local governments in colonial America. The Mayflower Compact was all but forgotten by the time of the Constitutional Convention, but the idea of self-government was still powerful. Therefore, even though the Mayflower Compact was quickly written out of necessity, it set a historic precedent toward the creation of a new democratic nation.
Text of the Mayflower Compact
The original document was lost, but the transcriptions in Mourt's Relation and William Bradford's journal Of Plymouth Plantation are in agreement and accepted as accurate. Bradford's hand written manuscript is kept in a special vault at the State Library of Massachusetts.[2] Bradford's transcription is as follows:
"In the name of God, Amen. We, whose names are underwritten, the loyal subjects of our dread sovereigne Lord, King James, by the grace of God, of Great Britaine, France, and Ireland king, defender of the faith, etc., having undertaken, for the glory of God, and advancement of the Christian faith, and honour of our king and country, a voyage to plant the first colony in the Northerne parts of Virginia, doe, by these presents, solemnly and mutually in the presence of God, and one another, covenant and combine ourselves together into a civil body politick, for our better ordering and preservation and furtherance of the ends aforesaid; and by virtue hereof to enacte, constitute, and frame such just and equall laws, ordinances, acts, constitutions, and offices, from time to time, as shall be thought most meete and convenient for the generall good of the Colonie unto which we promise all due submission and obedience. In witness whereof we have hereunder subscribed our names at Cap-Codd the 11. of November, in the year of the raigne of our sovereigne lord, King James, of England, France, and Ireland, the eighteenth, and of Scotland the fiftie-fourth. Anno. Dom. 1620."
(Original 1630s spelling):
In ye name of God, Amen. We whose names are underwriten, ye loyall subjects of our dread soveraigne Lord James I of England by ye grace of God, of Union of the Crowns, English claims to the French throne, & Kingdom of Ireland king, Fidei defensore faith, e&
Haveing undertaken, for ye glorie of god, and advancemente of ye Christian faith and honour of our king & countrie, a voyage to plant ye first colonie in ye Northerne parts of Virginia Company, doe by these presents solemnly & mutualy in ye presence of God, and one of another, covenant & combine our selves togeather into a civill body politick, for our better ordering & preservation & furtherance of ye ends aforesaid; and by vertue hearof to enacte, constitute, and frame such just & equall lawes, ordinances, Acts, constitutions, & offices, from time to time, as shall be thought most meete & convenient for ye generall good of ye Colonie, unto which we promise all due submission and obedience. In witnes wherof we have hereunder subscribed our names at Cap-Codd ye •11• of November, in ye year of ye raigne of our soveraigne Lord King James, of Kingdom of England, France, & Ireland ye eighteenth, and of Kingdom of Scotland ye fiftie fourth. Ano: Dom. 1620.[3]
The compact is often referred to as the foundation of the US Constitution of the United States,[4] in a figurative, not literal, way, although is often mistakenly thought to be the first Constitution in America. The Fundamental Orders of Connecticut actually hold this honor.
Signing of the Mayflower Compact, a painting by Edward Percy Moran, which hangs at the Plymouth Museum.
The list of 41 male passengers who signed was supplied by Bradford's nephew Nathaniel Morton in his 1669 New England's Memorial. There are no surviving first-hand accounts of this information.[5]
John Carver
John Alden
John Howland
Stephen Hopkins
Edward Winslow
Gilbert Winslow
Myles Standish
John Allerton
Isaac Allerton
John Billington
Thomas Tinker
Samuel Fuller
Edward Leister
Edward Tilly
John Craxton
Edward Fuller
Richard Gardiner
Edmund Margeson
George Soule
James Chilton
Francis Cooke
Edward Doty
Moses Fletcher
John Rigdale
William Mullins
Thomas English
Richard Bitteridge
Francis Eaton
John Tilly
↑ "The Mayflower Compact," Plymouth Plantation. The Mayflower Compact Retrieved January 13, 2008.
↑ State Library of Massachusetts Online catalog Retrieved January 13, 2008.
↑ Bradford, William (1898). "Book 2, Anno 1620", in Hildebrandt, Ted: Bradford's History "Of Plimoth Plantation" (PDF), Boston: Wright & Potter. Retrieved January 13, 2008.
↑ Adams, John Quincy (1802). in Manis, Jim: John Quincy Adams' Orations (PDF), Pennsylvania State University. Retrieved January 13, 2008.
↑ Morton, Nathaniel (1669). "2", in Rhys, Ernest: New England's Memorial. Bibliomania. Retrieved January 13, 2008.
Eliot, Charles William. American Historical Documents 1000-1904 With Introductions and Notes. The Harvard classics, v. 43. Whitefish, Mont.: Kessinger Publishing, 2004.
Haxtun, Annie Arnoux. Signers of the Mayflower Compact. Baltimore, Md: Reprinted for Clearfield by Genealogical Pub. Co, 1998. ISBN 9780806301730
Howe, Randy. Speak to Me Great American Texts Demystified for Today's Text-Messaging Students. New York: Kaplan, 2007.
Inc. Sterling Publishing Co. Let Freedom Ring The Words That Shaped Our America. New York: Sterling Pub, 2001. ISBN 9780806992877
Yero, Judith Lloyd. The Mayflower Compact. American documents. Washington, D.C.: National Geographic Society, 2006. ISBN 9780792258919
All links retrieved September 11, 2018.
Pilgrim Hall Museum: The Mayflower Compact
Mayflower Compact history
History of "Mayflower Compact"
Retrieved from http://web.newworldencyclopedia.org/p/index.php?title=Mayflower_Compact&oldid=1014438


text:
Business Valuation & Succession Planning
Conover Insurance
Conover Capital
Conover Tax
Built from the cloud up with the most innovative technologies, Workday is equipped to meet the unique needs of your industry.
Sub Menu Title
Conover Capital Management Blog
Bradley D. Green
Brad Green is a 1989 graduate of Arizona State University with a Bachelor of Arts degree in Business Administration. He joined New York Life as an agent in 1990 and spent three years in the company's agent development program, concentrating on business planning and financial services. While with New York Life, Brad qualified for the Million Dollar Round Table and President's Council several times. In 1991, he established Pacific Capital Resources (PCR), a successful employee benefits firm. He operated PCR until 1998, when he joined Conover as its Employee Benefits Manager. In 1999, he took over management of the Bellevue branch and was promoted to Corporate CEO in 2000.
Subscribe to get the latest insights
Capital Management can be confusing. Conover shares the latest industry news and tips to help make it clear.
Free Download - 10 Effective Sales Management Skils
A wonderful serenity has taken possession of my entire soul, like these sweet mornings of spring which I enjoy.
Features written in the form of a benefit statement
Bullets are great for spelling out benefits
Turning visitors into Leads with great bullets
"Delivering on our promises by empowering people and exceeding expectations."
Need support? You can also visit our contact page for more information.
155 108th Ave NE, Suite 725, Bellevue, WA, 98004-5948
info@conovercapital.com
Advisory services provided through Conover Capital Management LLC, an SEC Registered Investment Advisor. Securities offered through Conover Securities Corporation MEMBER FINRA / SIPC. Conover Capital Management LLC is an affiliate of Conover Securities Corporation.
© 2018 Conover Capital Management
Conover Companies
ConoverAVI
Conover Life Insurance Services
Conover Tax & Accounting
Conover Capital Management
Conover Securities Corporation
Conover Administration
155 108th Ave NE, Suite 725,Bellevue, WA, 98004-5948
Visit our contact page for more information.
Conover Capital © 2021. All rights reserved.
Advisory services provided through Conover Capital Management LLC, an SEC Registered Investment Advisor.
Securities offered through Conover Securities Corporation MEMBER FINRA / SIPC. Conover Capital Management LLC is an affiliate of Conover Securities Corporation.


text:
6 Labels / Record Deals 3 Song placements 1 Management Deals
9 fully mastered 9 broadcast ready 7 rough mixes
7 Yes 2 No
2 within 45 days 7 longer than 45 days
Shopping Artists for Roster Inclusion for Upcoming Record Label
Seeking exciting new artists for roster inclusion for upcoming Parliament Records.
After years of working with top industry leaders including Tony Bongiovi and his team at Power Station, as well as national recording artists and some of America's largest independent labels, Parliament Publishing is now broadening it's presence to include a record label in 2020.
We are seeking exciting, upcoming recording artists in the realms of rock, pop, and dance. Country and rap acceptable if professionally-produced.
- Shayne Leighton - Licensing Manager - Parliament House Publishing
Deal Type: Label Signing
Decision Maker: Selected artists will be pitched for final decision
Compensation: $5,001 - $10,000
Similar Sounding Artists: Ariana Grande, Taylor Swift, Katy Perry, Mumford & Sons, Bleachers
Def Jam Looking for New Artists for Record Deal
Def Jam Recordings is seeking outstanding artists for a full record deal. We want an artist that can do it all. If you think you belong on our US roster, which you can see here: www.defjam.com/artists and you have what it takes to make it in today's hyper-competitive music environment, we want to hear what you have before you submit it anywhere else!
Def Jam is home to some of today's music greats and if you belong among them we want to be the first to know.
- Jason "Polo" Carbonell / Def Jam Recordings
Deal Type: Record Deal
Compensation: Negotiable
Similar Sounding Artists: Please see our artist roster HERE
Def Jam Looking for Singles for Single Deal
Do you have an amazing single ready for worldwide release? We want to hear it! If you think your song belongs on our US roster, which you can see here: www.defjam.com/artists and you have what it takes to make it in today's hyper-competitive music environment, we want to hear what you have before you submit it anywhere else!
Deal Type: Single Deal
Interscope Records / Ray Daniels Seeking Great R&B Tracks for Artists already on our Roster
Ray Daniels, SVP A&R at Interscope Records, is seeking great R&B tracks for artists already on the Interscope Roster, which can bee seen HERE.
If you have a great track with the right ingredients, we can't wait to hear it. Please submit you best work for consideration and a note about what artist(s) you think the song would be appropriate for. If we love it we'll take things to the next step.
- Ray Daniels / SVP A&R Interscope Records (Universal Music Group)
Deal Type: Song Placement - Interscope Records Artist
Similar Sounding Artists: See a full list of current Interscope Records artists HERE
Interscope Records / Ray Daniels Seeking Authentic R&B (Both Male & Female)
Ray Daniels, SVP of A&R for Interscope Records, is seeking authentic R&B. It can be performed by either male or female vocalists.
If you have what it takes and believe you belong on our roster next to greats like Madonna and newcomers like Selena Gomez, let's hear your best material. If we love it we'll take things to the next step.
Seeking Music for rapper Ty Dolla $ign
I'm seeking new music (beats, tracks, hooks etc.) for rapper Ty Dolla $ign. This is for his follow up to the 2015 hit album Free TC. Ty Dolla $ign sings and raps, combining elements of hip hop and contemporary R&B.
I'll be pitching tracks directly to his team at Atlantic Records. Please submit your best track(s) for consideration.
- Terence LeMaile / Brand B Sports
Deal Type: Song Placement
Decision Maker: Selected tracks will be pitched for final decision
Similar Sounding Artists: Wiz Khalifa, YG, DJ Mustard, Kid Ink, RJ, Joe Moses, Jeremih, Trey Songz, Omarion
Def Jam Looking for Hip Hop, R&B, Trap and Pop beats for Artist Placements
Def Jam Recordings is seeking outstanding hip-hop, R&B, trap and pop beats for placements with our artists. The label focuses primarily on hip-hop and urban music, but we have a diverse roster and looking for talent that can do it all, working with a variety of our artists and cross-genres. Please submit your best track(s) for consideration, and let us know if there's a particular artist on our roster you think the beat would work for.
Deal Type: Beat Placement
Roster Music seeks Commercial "Dance" Acts & Music
We are seeking great new "dance" tracks and artists from all over the world.
If you've got something special, we are eager to hear it and if we can use it, we'll be in touch.
Our current roster boasts artists such as Henry Mendez, Serebro, Michel Teló, DJ Antoine, Charly Rodriguez, Afrojack, Gusttavo Lima...
This is where we attend music submissions. Please do not contact us outside Music Xray. This is where we manage our music submissions.
- Roster Music


The best ski lessons and videos.
Freestyle ski tutorial showing How To nose butter on skis with Mike Henitiuk.
Freestyle ski tutorial showing How To nose butter on skis.
Tutorial for better Lateral Balance. Improve your skiing and control with this free intermediate's ski video lesson.
Learn a little about the physics of skiing with this free intermediate's ski video lesson.
Learn the how to do 180's and 360's on skis with this free ski tutorial on spin tricks from Bergfex GmbH.
Get started on butter 180's and 360's on skis with this free ski tutorial from Bergfex GmbH.
Learn the fundamentals for skiing tricks on rails and boxes with this free ski tutorial from Bergfex GmbH.
Learn the how to do switch 180's on skis with this free ski tutorial on spin tricks from Ski Addiction.
Freestyle ski tutorial showing How To to learn 360 spins on skis.
Freestyle ski tutorial showing how to do a backflip on skis.


stone ore processing line small jaw crusher for sale Small Jaw Crushers Wholesale, Crushers Suppliers. Used Small Pe 150X250 Stone Jaw Crusher For Sale Factory Price Small Mini Rock Stone Jaw Crusher Machine . small jaw crusher for sale stone crushing plant.
Used Small Mobile Crusher Plant Processing Line. crusher - used machine crushing plant. a crusher is a machine designed to reduce large rocks into smaller rocks,gravel,or rock dust.crushers may be used to reduce the .
Quartz jaw crusher processing of crushing plant canada ... Machine Equipment Price For Crushing Marble Concrete Barite Limestone Quartz Ore . Mini Small Scale Size Used Quartz Gravel Rock Salt Sand Gold Stone Make Crush .
Product 1 16 Small Stone Crusher Machine For Sale,Mining Equipment Suppliers in SCMsmall China Mini Gold Washing Plant, Small Portable Gold Ore . india mobile unit iron ore small rock crusher for sa Mineral Processing,Equipment.
semi mobile impact crusher plant voest hazemag; mobile crusher fujairah; used stone crushing machine line suppliers; sand core making process for moulding; metal mining crushing plants for sale; ... small used gold mining equipment for sale in australia. suppliers of mining equipment.
Fix type plant mobile trommel gold washing machine used in. Fix Type Plant Mobile Trommel Gold Washing Machine Used In Ghana Africa . fed systems, while maintaining large scale production with a smaller footprint. . lead, zinc, tantalum and some non-ferrous metals like quart, zircon, barite,ect. .
limestonestone crushers second hand processing line quartz sand second hand sand making second hand 200 tph stone crusher plant in india. second hand 200 tph demand for crushing stone in india Home>>Indian Mining Equipment>>mobile stone crushers demand in india.Quartz Processing is limestonestone crusher machine in production line.
Mobile Primary Jaw Crusher · HPT Series Non-Metallic Ore · Cu-Pb-Zn-Dressing-Process · Stone Crushing Line Quartz Sand Dressing Production Line. Rock Crushers 911 Metallurgist Feb 6, 2017 The jaw crushers is an intermittent machine, that is, crushing is done through a fraction of .


text:
HI helps anti-personnel victim Ismail live with dignity again
Armed violence reduction | Insertion | Rehabilitation | Lebanon | PUBLISHED ON September 28th 2020
Ismail is pleased with his new prostheses | © HI
Ismail lost both legs in a landmine explosion at the age of 14. HI is now teaching him to walk again with his new prostheses.
Injured by an anti-personnel mine in 2014, Ismael had to have both legs amputated above the knee. The accident turned his life upside down and left him feeling excluded. Without adapted prostheses, he is reliant on others and unable to do routine activities.
Now 17, Ismail grew out of his last pair of prostheses, which became too small for him and he needed new ones
"Because Ismail's prostheses were too small, they were uncomfortable and could have caused him complications, preventing him from moving around unaided," explains HI physiotherapist Rana Al Adbel.
HI's rehabilitation teams assessed his physical condition and supplied him with new prostheses adapted to his size, allowing him to continue walking and living normally.
Living with dignity
Ismail lives with his parents and five siblings aged five to twenty-seven in a very isolated and inaccessible rural area.
They have been directly impacted by the COVID-19 pandemic because they can no longer afford to buy essential items, such as food.
As the situation is still unstable and dangerous in his home region, Ismail does not wish to return to live in Syria.
He prefers to take a training course and find a stable job.
"I want to earn enough money for my family to live with dignity," he says.
Advocacy Health Insertion Laws Prevention
Ensure disability inclusion is not just a tick mark
HI's three approaches to greener assistive devices
1 million square meters cleared by HI over 10 years